ABSTRACT
Purpose
To evaluate the efficacy and safety of 0.05% cyclosporine eye drops (II) for the treatment of primary Sjögren’s syndrome-associated dry eye (PSSDE).
Methods
Sixty patients with PSSDE were randomly divided into three groups, received treatment with 0.05% cyclosporine (C group), artificial tears (S group) or their combination (CS group). The evaluation indicators were evaluated at baseline and at weeks 2, 4 and 12.
Results
The symptoms of C and CS groups were reduced significantly. The signs [schirmer I test (F = 4.838, p = .011), ocular staining score (F = 7.961, p = .001) and tear break-up time (F = 9.283, p < .001)] were significantly different between S and C groups as well as S and CS groups. The tear meniscus height (F = 3.197, p = .048) was significantly different between S and CS groups. No serious adverse events occurred.
Conclusion
0.05% cyclosporine is an effective and safe treatment for patients with PSSDE.
Acknowledgments
The authors would like to express their gratitude to the ophthalmological nurses of The Second Hospital of Dalian Medical University for their help and EditSprings (https://www.editsprings.cn/) for the expert linguistic services provided.
Disclosure statement
No potential conflict of interest was reported by the authors.
Author contributions
Conceptualization & Methodology, Mingjun Gao, Lin Zhao; Data Collection, Ran Liang; Software & Data Analysis, Qing Zhu; Writing-Review & Editing, Mingjun Gao; Conceptualization, Methodology and Support Contributions, Qi Zhao, Xiaodan Kong.